Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kari Remes

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
British Journal of Haematology|December 5, 2012
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patientsRaija Silvennoinen, Veli Kairisto, Tarja-Terttu Pelliniemi, et al.
Plos One|December 6, 2018
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013Kari Remes, Pekka Anttila, Raija Silvennoinen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow TransplantationKate Cwynarski, Anja van Biezen, Liesbeth de Wreede, et al.
Bone Marrow Transplantation|September 2, 2024
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patientsMats Brune, Thomas Kiss, Harald Anderson, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2020
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Christian Berthou, Miguel Hernandez, et al.
Cytometry. Part B, Clinical Cytometry|June 10, 2010
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myelomaHans E Johnsen, Martin Bøgsted, Tobias W Klausen, et al.
European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.
European Journal of Haematology|September 18, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study GroupHenrik Gregersen, Valdas Peceliunas, Kari Remes, et al.
Blood|April 26, 2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialUlf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, et al.
Blood|June 21, 2011
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemiaBengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
British Journal of Haematology|December 5, 2012
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patientsRaija Silvennoinen, Veli Kairisto, Tarja-Terttu Pelliniemi, et al.
Plos One|December 6, 2018
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013Kari Remes, Pekka Anttila, Raija Silvennoinen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow TransplantationKate Cwynarski, Anja van Biezen, Liesbeth de Wreede, et al.
Bone Marrow Transplantation|September 2, 2024
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patientsMats Brune, Thomas Kiss, Harald Anderson, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2020
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Christian Berthou, Miguel Hernandez, et al.
Cytometry. Part B, Clinical Cytometry|June 10, 2010
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myelomaHans E Johnsen, Martin Bøgsted, Tobias W Klausen, et al.
European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.
European Journal of Haematology|September 18, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study GroupHenrik Gregersen, Valdas Peceliunas, Kari Remes, et al.
Blood|April 26, 2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialUlf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, et al.
Blood|June 21, 2011
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemiaBengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, et al.
Pageof 4